Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

<strong>Objectives</strong> This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate (MTX), or MTX over 1 year. Cumulative pain and quality of life benefits we...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Taylor, P, Alten, R, Álvaro-Gracia, JM, Kaneko, Y, Walls, C, Quebe, A, Jia, B, Bello, N, Terres, JR, Fleischmann, RM
Formáid: Journal article
Teanga:English
Foilsithe / Cruthaithe: BMJ Publishing Group 2022
_version_ 1826307741021372416
author Taylor, P
Alten, R
Álvaro-Gracia, JM
Kaneko, Y
Walls, C
Quebe, A
Jia, B
Bello, N
Terres, JR
Fleischmann, RM
author_facet Taylor, P
Alten, R
Álvaro-Gracia, JM
Kaneko, Y
Walls, C
Quebe, A
Jia, B
Bello, N
Terres, JR
Fleischmann, RM
author_sort Taylor, P
collection OXFORD
description <strong>Objectives</strong> This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate (MTX), or MTX over 1 year. Cumulative pain and quality of life benefits were also assessed. <br><strong> Methods </strong>Randomised, double-blind, phase 3 study RA-BEGIN (NCT01711359) compared baricitinib 4 mg (N=159), baricitinib 4 mg +MTX (N=215) and MTX (N=210) in patients with RA who had no or limited prior disease-modifying antirheumatic drug treatment. Pain was assessed on a 0–100 mm Visual Analogue Scale (VAS). Proportion of patients with ≥30%, ≥50% and ≥70% pain improvement from baseline; ≤20 mm and ≤10 mm on the pain VAS; and time to achieve pain improvement thresholds were assessed over 52 weeks, as were Patient Global Assessment (PtGA) and 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS) outcomes. <br><strong> Results </strong>Baricitinib monotherapy or combination with MTX provides greater (least square mean changes (LSM) from baseline −40 mm and −43 mm, respectively) and more rapid (median 12 and 8 weeks to ≥70% improvement, respectively) pain relief than MTX alone (LSM −31 mm, median 20 weeks to ≥70% improvement) over 52 weeks. Baricitinib, alone or combination, provides 9–10 additional weeks of limited to no pain, similar gain in achievable wellness measured through PtGA, and 5–7 additional weeks with change in SF-36 PCS ≥5 vs MTX over 1 year. <br><strong> Conclusions </strong>Patients treated with baricitinib reported significantly greater and more rapid pain relief, more weeks with limited to no pain, and clinically meaningful improvements in physical health than patients treated with MTX alone over 1 year.
first_indexed 2024-03-07T07:07:40Z
format Journal article
id oxford-uuid:5e1b317d-b45f-4ed7-af76-f3a1f9a45b65
institution University of Oxford
language English
last_indexed 2024-03-07T07:07:40Z
publishDate 2022
publisher BMJ Publishing Group
record_format dspace
spelling oxford-uuid:5e1b317d-b45f-4ed7-af76-f3a1f9a45b652022-05-19T13:52:26ZAchieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5e1b317d-b45f-4ed7-af76-f3a1f9a45b65EnglishSymplectic ElementsBMJ Publishing Group2022Taylor, PAlten, RÁlvaro-Gracia, JMKaneko, YWalls, CQuebe, AJia, BBello, NTerres, JRFleischmann, RM<strong>Objectives</strong> This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate (MTX), or MTX over 1 year. Cumulative pain and quality of life benefits were also assessed. <br><strong> Methods </strong>Randomised, double-blind, phase 3 study RA-BEGIN (NCT01711359) compared baricitinib 4 mg (N=159), baricitinib 4 mg +MTX (N=215) and MTX (N=210) in patients with RA who had no or limited prior disease-modifying antirheumatic drug treatment. Pain was assessed on a 0–100 mm Visual Analogue Scale (VAS). Proportion of patients with ≥30%, ≥50% and ≥70% pain improvement from baseline; ≤20 mm and ≤10 mm on the pain VAS; and time to achieve pain improvement thresholds were assessed over 52 weeks, as were Patient Global Assessment (PtGA) and 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS) outcomes. <br><strong> Results </strong>Baricitinib monotherapy or combination with MTX provides greater (least square mean changes (LSM) from baseline −40 mm and −43 mm, respectively) and more rapid (median 12 and 8 weeks to ≥70% improvement, respectively) pain relief than MTX alone (LSM −31 mm, median 20 weeks to ≥70% improvement) over 52 weeks. Baricitinib, alone or combination, provides 9–10 additional weeks of limited to no pain, similar gain in achievable wellness measured through PtGA, and 5–7 additional weeks with change in SF-36 PCS ≥5 vs MTX over 1 year. <br><strong> Conclusions </strong>Patients treated with baricitinib reported significantly greater and more rapid pain relief, more weeks with limited to no pain, and clinically meaningful improvements in physical health than patients treated with MTX alone over 1 year.
spellingShingle Taylor, P
Alten, R
Álvaro-Gracia, JM
Kaneko, Y
Walls, C
Quebe, A
Jia, B
Bello, N
Terres, JR
Fleischmann, RM
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
title Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
title_full Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
title_fullStr Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
title_full_unstemmed Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
title_short Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
title_sort achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
work_keys_str_mv AT taylorp achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT altenr achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT alvarograciajm achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT kanekoy achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT wallsc achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT quebea achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT jiab achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT bellon achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT terresjr achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy
AT fleischmannrm achievingpaincontrolinearlyrheumatoidarthritiswithbaricitinibmonotherapyorincombinationwithmethotrexateversusmethotrexatemonotherapy